Pinnacle Financial Partners Inc Has $9.15 Million Holdings in Zoetis Inc. $ZTS

Pinnacle Financial Partners Inc lifted its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 34.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 62,531 shares of the company’s stock after purchasing an additional 16,080 shares during the quarter. Pinnacle Financial Partners Inc’s holdings in Zoetis were worth $9,150,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in ZTS. Halbert Hargrove Global Advisors LLC increased its stake in Zoetis by 496.6% during the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock worth $25,000 after acquiring an additional 144 shares during the period. REAP Financial Group LLC grew its holdings in shares of Zoetis by 201.5% during the 2nd quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock worth $31,000 after purchasing an additional 131 shares in the last quarter. NewSquare Capital LLC increased its position in shares of Zoetis by 69.1% in the second quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock worth $32,000 after purchasing an additional 85 shares during the period. ORG Partners LLC raised its stake in Zoetis by 56.8% in the second quarter. ORG Partners LLC now owns 232 shares of the company’s stock valued at $37,000 after purchasing an additional 84 shares in the last quarter. Finally, Financial Consulate Inc. acquired a new position in Zoetis in the third quarter valued at about $39,000. 92.80% of the stock is currently owned by institutional investors.

Zoetis Stock Down 0.4%

Shares of NYSE:ZTS opened at $124.79 on Friday. Zoetis Inc. has a 52-week low of $115.25 and a 52-week high of $177.40. The company has a market capitalization of $54.99 billion, a PE ratio of 21.01, a price-to-earnings-growth ratio of 2.53 and a beta of 0.97. The company has a debt-to-equity ratio of 1.31, a quick ratio of 2.28 and a current ratio of 3.64. The company has a fifty day moving average of $123.21 and a 200-day moving average of $139.49.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. Zoetis had a return on equity of 57.19% and a net margin of 28.21%.The business had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.42 billion. During the same quarter in the previous year, the company posted $1.58 EPS. Zoetis’s quarterly revenue was up .5% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 3rd. Investors of record on Tuesday, January 20th will be given a dividend of $0.53 per share. The ex-dividend date is Tuesday, January 20th. This represents a $2.12 annualized dividend and a yield of 1.7%. This is a boost from Zoetis’s previous quarterly dividend of $0.50. Zoetis’s dividend payout ratio is 35.69%.

Analyst Upgrades and Downgrades

ZTS has been the topic of several recent analyst reports. HSBC set a $140.00 target price on shares of Zoetis in a report on Wednesday, December 10th. Stifel Nicolaus decreased their price objective on shares of Zoetis from $140.00 to $130.00 and set a “hold” rating on the stock in a research note on Tuesday, November 18th. Bank of America cut Zoetis from a “buy” rating to a “neutral” rating and set a $135.00 target price for the company. in a research note on Monday, December 15th. UBS Group decreased their price target on Zoetis from $158.00 to $141.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 5th. Finally, Morgan Stanley set a $160.00 price objective on Zoetis in a research report on Thursday, December 18th. Six research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat.com, Zoetis presently has an average rating of “Hold” and an average target price of $160.18.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.